Overcoming Financial Barriers to Optimal Guideline-Directed Medical Therapy for Patients With Heart Failure

Ronald J Campbell1, Jennifer Kliner2, Heather Goetze1

  • 1Department of Pharmacy, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.

JACC. Case Reports
|March 7, 2025
PubMed

Insights

Financial barriers to heart failure with reduced ejection fraction (HFrEF) medications can be overcome. A medication optimization clinic helped a patient access all four pillars of guideline-directed medical therapy (GDMT) using patient assistance resources.

Area of Science:

  • Cardiology
  • Pharmacoeconomics
  • Patient Care

Background:

  • Optimizing guideline-directed medical therapy (GDMT) is crucial for managing heart failure with reduced ejection fraction (HFrEF).
  • The high cost of novel HFrEF medications presents a significant financial challenge for many patients.
  • Team-based care models can identify and leverage resources to mitigate these financial barriers.

Purpose of the Study:

  • To illustrate how patient assistance resources can facilitate access to GDMT for HFrEF.
  • To highlight the role of medication optimization clinics in overcoming cost-related treatment gaps.

Main Methods:

  • A case study approach was used, focusing on a 79-year-old female patient with HFrEF.
  • The patient's access to all four pillars of GDMT was evaluated.
  • Utilization of patient assistance programs through a specialized clinic was central to the intervention.

Main Results:

  • The patient successfully gained access to all four pillars of guideline-directed medical therapy.
  • Patient assistance resources effectively addressed the financial barriers associated with prescribed medications.
  • The medication optimization clinic played a key role in navigating and securing these resources.

Conclusions:

  • Patient assistance resources are vital for ensuring equitable access to optimal HFrEF treatment.
  • Medication optimization clinics are effective in facilitating team-based care to overcome financial obstacles in GDMT.
  • This case demonstrates a successful strategy for improving HFrEF management by addressing medication affordability.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
360
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
303
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
318
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
488
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K